Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AQSZF is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this stock must be the cheapest Biotech out there .Stock should be at minimum $2+ right now .
http://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf
File for CDN approval of Topiramate XR and Oxcarbazepine XR
Operational profitability estimated in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
Got a great Reply by Ceo Janzen ..this unknown Goldmine should be at $2+ right now ...Bought my shares back in last few days .
djanzen@aequuspharma.ca Jan 6 at 10:13 PM
Hello XXX and Happy New Year… Thanks for your email.
The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings.
Happy to chat if you would like to have a phone call…
Best, Doug Janzen Chairman and CEO / CoFounder Aequus Pharmaceuticals
Another great news out today
Great News and Stock is still brutally underpriced ....
Dror Ben-Asher, Chief Executive Officer of RedHill, said: "We are pleased to partner with Concordia for the U.S. promotion of Donnatal®, a trusted brand among physicians for symptoms of IBS and acute enterocolitis5. With a core U.S. commercial team in place, we plan to initiate promotional activities in the U.S. in the coming months with a specialty gastrointestinal sales force. RedHill`s strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with commercial presence in the U.S., is planned to support potential future commercialization of our Phase III-stage potential blockbusters BEKINDA® for gastroenteritis and other GI indications, RHB-105 for H. pylori infection and RHB-104 for Crohn`s disease, if approved by FDA."
Great Analysis by J.Napodano he says stock should valued at $500 M ( currently around $150 M includes new shares offering)
RedHill Expects An Eventful Next Few Months
http://www.talkmarkets.com/content/stocks--equities/redhill-expects-an-eventful-next-few-months?post=112761
That being said, I believe RedHill BioPharma is worth approximately $500 million in value today. I see the most valuable asset as RHB-104 for Crohn's disease, followed by RHB-105 for H. pylori infection. Other important assets include Bekinda for gastroenteritis and IBS-D, RHB-104 for MS, and Yeliva and Mesupron in mid-stage development for various oncology indications. The company held $40.5 million in cash as of September 30, 2016, of which I'm including only $25 million into my sum-of-parts analysis. The company has no debt.
Great Analysis by J.Napodano he says stock should valued at $500 M ( currently around $150 M includes new shares offering)
RedHill Expects An Eventful Next Few Months
http://www.talkmarkets.com/content/stocks--equities/redhill-expects-an-eventful-next-few-months?post=112761
That being said, I believe RedHill BioPharma is worth approximately $500 million in value today. I see the most valuable asset as RHB-104 for Crohn's disease, followed by RHB-105 for H. pylori infection. Other important assets include Bekinda for gastroenteritis and IBS-D, RHB-104 for MS, and Yeliva and Mesupron in mid-stage development for various oncology indications. The company held $40.5 million in cash as of September 30, 2016, of which I'm including only $25 million into my sum-of-parts analysis. The company has no debt.
Great Analysis by J.Napodano he says stock should valued at $500 M ( currently around $150 M includes new shares offering)
RedHill Expects An Eventful Next Few Months
http://www.talkmarkets.com/content/stocks--equities/redhill-expects-an-eventful-next-few-months?post=112761
That being said, I believe RedHill BioPharma is worth approximately $500 million in value today. I see the most valuable asset as RHB-104 for Crohn's disease, followed by RHB-105 for H. pylori infection. Other important assets include Bekinda for gastroenteritis and IBS-D, RHB-104 for MS, and Yeliva and Mesupron in mid-stage development for various oncology indications. The company held $40.5 million in cash as of September 30, 2016, of which I'm including only $25 million into my sum-of-parts analysis. The company has no debt.
RDHL the next big higherflyer in the bio sector
RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?
http://www.bionapcfa.com/2015/10/redhill-biopharmas-rhb-104-potential.html
The opportunity for RedHill Biopharma with RHB-104 looks significant. If the Phase 3 trial is successful, I think the market will start to view RHB-104 as having peak sales in the $500-750 million range for the U.S., with potential expansion to over one billion on a global basis.
------
Dan Suesskind , Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently.
More Infos about this undiscovered Goldmine ....
RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?
http://www.bionapcfa.com/2015/10/redhill-biopharmas-rhb-104-potential.html
The opportunity for RedHill Biopharma with RHB-104 looks significant. If the Phase 3 trial is successful, I think the market will start to view RHB-104 as having peak sales in the $500-750 million range for the U.S., with potential expansion to over one billion on a global basis.
------
Dan Suesskind , Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently.
More Infos about RDHL
RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?
http://www.bionapcfa.com/2015/10/redhill-biopharmas-rhb-104-potential.html
The opportunity for RedHill Biopharma with RHB-104 looks significant. If the Phase 3 trial is successful, I think the market will start to view RHB-104 as having peak sales in the $500-750 million range for the U.S., with potential expansion to over one billion on a global basis.
------
Dan Suesskind , Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently.
RDHL is massive undervalued and heavily oversold should rebound to $11+ quickly .
RDHL (MC $150M) $70+M Cash 3 BLOCKBUSTER Drugs with P3 results in 1H 2017 = Next 10+ BAGGER GEM
RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year .
Market Cap :$148 Million
Cash: $62 Million
Price: 9.70
Shares out 15 Million (50% of Shares held by Insiders alone)
New Presentation
http://files.shareholder.com/downloads/AMDA-1C0OBF/3449232654x0x921626/E74E4AE5-D2D2-4BE5-AC65-E5500A956C12/RedHill_Biopharma_Corporate_Presentation_151216_.pdf
Upcoming Milestones Q4 2016:
Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.
1H 2017 :
RIZAPORT®(RHB-103):
•Re-submission of U.S. NDA
RHB-104:
[B]•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017 <<<<<<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $5+ BILLION
BEKINDA®(RHB-102):
•Top-line Phase III results (gastroenteritis) -mid-2017 <<<< MARKET SIZE $650+ MILLION
•Top-line Phase II results (IBS-D) -mid-2017
RHB-105 (H. pylori):
First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017 <<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $4+ Billion
RDHL (MC $150M) $70+M Cash 3 BLOCKBUSTER Drugs with P3 results in 1H 2017 = Next 10+ BAGGER GEM
RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year .
Market Cap :$148 Million
Cash: $62 Million
Price: 9.70
Shares out 15 Million (50% of Shares held by Insiders alone)
New Presentation
http://files.shareholder.com/downloads/AMDA-1C0OBF/3449232654x0x921626/E74E4AE5-D2D2-4BE5-AC65-E5500A956C12/RedHill_Biopharma_Corporate_Presentation_151216_.pdf
Upcoming Milestones Q4 2016:
Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.
1H 2017 :
RIZAPORT®(RHB-103):
•Re-submission of U.S. NDA
RHB-104:
[B]•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017 <<<<<<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $5+ BILLION
BEKINDA®(RHB-102):
•Top-line Phase III results (gastroenteritis) -mid-2017 <<<< MARKET SIZE $650+ MILLION
•Top-line Phase II results (IBS-D) -mid-2017
RHB-105 (H. pylori):
First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017 <<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $4+ Billion
RDHL (MC $150M) $60+M Cash 3 MEGA Drugs with P3 results in 1H 2017
RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year .
Market Cap :$148 Million
Cash: $62 Million
Price: 9.70
Shares out 15 Million (50% of Shares held by Insiders alone)
New Presentation
http://files.shareholder.com/downloads/AMDA-1C0OBF/3449232654x0x921626/E74E4AE5-D2D2-4BE5-AC65-E5500A956C12/RedHill_Biopharma_Corporate_Presentation_151216_.pdf
Upcoming Milestones Q4 2016:
Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.
1H 2017 :
RIZAPORT®(RHB-103):
•Re-submission of U.S. NDA
RHB-104:
[B]•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017 <<<<<<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $5+ BILLION
BEKINDA®(RHB-102):
•Top-line Phase III results (gastroenteritis) -mid-2017 <<<< MARKET SIZE $650+ MILLION
•Top-line Phase II results (IBS-D) -mid-2017
RHB-105 (H. pylori):
First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017 <<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $4+ Billion
Im back in on this brutally undervalued and almost unknown gem . There is a lot of News coming within next 6-7 months to drive this Low Float stock to new All Time Highs .Share Offering creates a fantastic buying opportunity today .GL
New Presentation
http://files.shareholder.com/downloads/AMDA-1C0OBF/3449232654x0x921626/E74E4AE5-D2D2-4BE5-AC65-E5500A956C12/RedHill_Biopharma_Corporate_Presentation_151216_.pdf
Upcoming Milestones Q4 2016:
Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.
1H 2017 :
RIZAPORT®(RHB-103):
•Re-submission of U.S. NDA
RHB-104:
•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017
BEKINDA®(RHB-102):
•Top-line Phase III results (gastroenteritis) -mid-2017
•Top-line Phase II results (IBS-D) -mid-2017
RHB-105 (H. pylori):
First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017
BURN-RATE $400 M PER Q + $3BILLION DEBT + RUNNINGOUT OF CASH = DELISTING + BANKRUPTCY FILING ON THE WAY = TGT $0
Rallyy continues and its still dirt cheap
Aequus Obtains Ontario Provincial Listing for Vistitan(TM)
http://www.stockhouse.com/news/press-releases/2016/09/29/aequus-obtains-ontario-provincial-listing-for-vistitan
"This is a major milestone since the launch of PrVistitan™ as Ontario accounts for over 40% of prescription volume in the prostaglandin class of medications," said Ian Ball, Chief Commercial Officer at Aequus. "Improved access to PrVistitan™ in Canada's largest market is expected to drive revenues towards during the remainder of 2016 and beyond."
Rallyy continues and its still dirt cheap
Aequus Obtains Ontario Provincial Listing for Vistitan(TM)
http://www.stockhouse.com/news/press-releases/2016/09/29/aequus-obtains-ontario-provincial-listing-for-vistitan
"This is a major milestone since the launch of PrVistitan™ as Ontario accounts for over 40% of prescription volume in the prostaglandin class of medications," said Ian Ball, Chief Commercial Officer at Aequus. "Improved access to PrVistitan™ in Canada's largest market is expected to drive revenues towards during the remainder of 2016 and beyond."
$1++ coming
Good News
Aequus Obtains Ontario Provincial Listing for Vistitan(TM)
http://www.stockhouse.com/news/press-releases/2016/09/29/aequus-obtains-ontario-provincial-listing-for-vistitan
"This is a major milestone since the launch of PrVistitan™ as Ontario accounts for over 40% of prescription volume in the prostaglandin class of medications," said Ian Ball, Chief Commercial Officer at Aequus. "Improved access to PrVistitan™ in Canada's largest market is expected to drive revenues towards during the remainder of 2016 and beyond."
load up guys while its still dirt cheap
Great Management here / Massive undervalued ( Market cap $13.9 M) / New Deals regarding In and Outlicensing on the way . This undiscovered stock is a great buying opportunity with tremendous upside potential .GL
http://redirect.viglink.com/?key=bbb516d91daee20498798694a42dd559&u=http%3A//www.aequuspharma.ca/investors/press-release/aequus-provides-corporate-update-on-commercial-and-development-programs
Once-Weekly Transdermal Aripiprazole
Patch Positive Proof of Concept Clinical Data for Once-Weekly Transdermal Aripiprazole Patch: Aequus’ once-weekly transdermal aripiprazole program is being developed for the treatment of certain psychiatric disorders. In the first half of 2016, Aequus announced positive results from an initial Proof of Concept clinical study, which suggested the current formulation may provide sustained, seven-day delivery of therapeutic doses of aripiprazole. Aequus is preparing for the follow-on, multi-dose bioavailability study expected to be initiated in the second half of 2016. Aequus has also expanded the patent portfolio for this program, with a patent issued / allowed in five major countries or regions, including the US, Russia, Mexico, Japan and Australia, and pending in multiple additional territories. Aequus owns worldwide rights to the formulation described in the issued patent, and will look to partner commercial rights in markets outside of Canada as the program continues to advance.
Long-Acting Transdermal Anti-Nausea Patch
Advancement of IP and Formulation Optimization for Long-Acting Transdermal Anti-Nausea Patch: Aequus is advancing a once-daily and up to a once-weekly transdermal doxylamine and pyridoxine combination patch for the treatment of nausea and vomiting in pregnancy (NVP). During the first half of 2016, the Company completed preclinical studies and expects to advance the current formulation into Proof of Concept clinical studies in the second half of 2016. Aequus has filed an international patent that covers the current formulation and has ownership of worldwide rights.
Aequus has been engaging with third parties around partnering discussions for each of its internal programs, with a goal of ensuring the maximum benefit is realized by shareholders.
---------------
Ian Ball – Former Global Head of Brand Maximization and Lifecycle Strategy with Novartis
?Strong relationships with key executives at Novartis and Sandoz
?Ability to structure low-upfront deals for valuable products
once investors discover this goldmine then it will hit $1 in no time
Total Market cap is c$16.2 Million (= US$12.4 Million)
AQSZF (MC $11 M) 2 Marketed Drugs +3 Drugs nearing Approval = 1000%+ UPSIDE POTENTIAL ..
This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in early 2017 .Peak sales for these 4 drugs is between $40-45 Million according to Management which is HUGE for this microcap stock with a ridiculous market cap of $10 Million .Management alone holding over 16 Million shares Ceo just bought 840k shares at 0.30 a few days ago . PT is $4-5 for this unknown Goldmine .GL
Aequus Pharma (AQS.V) (AQSZF)
Market-Cap: $11 M
Price: 0.22
Shares out: 54 Million
Presentation August 2016
http://www.aequuspharma.ca/Investors/Aequus%20Pharmaceuticals%20August%202016.pdf
Marketed Products :
Tacrolimus IR
Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)
Vistitan
•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.
Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017
Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017
NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)
exactly the main listing is in canada and here is the answer regarding the Insider holding which is very strong (Management alone holding over 16 Million shares ):
James West: All right. So then tell me about, how was your company capitalized, and what’s sort of the lay of the land in terms of institutional versus insiders versus retail?
Doug Janzen: We funded the business, we started kind of end of Q1 of 2013, and we raised a bit over $4 million privately for the business. We did an institutional round of $4 million led by Cormark in 2014, and then last year, we raised about $3.5 million in Q4 from retail in Canada and the U.S. So I’d say right now, the business is about 40 per cent held by founders and insiders, and about 30 per cent held by institutional accounts, and 30 per cent by retail high net worth.
Interview with Ceo Doug Janzen
http://business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canada
James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?
Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.
James West: Sure. Have you built a pharmaceutical company before, Doug?
Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.
Sep 19/16 Janzen, Doug Direct Ownership Common Shares 10 - Acquisition in the public market 9,000 $0.290
Sep 19/16 Janzen, Doug Direct Ownership Common Shares 10 - Acquisition in the public market 1,000 $0.285
Sep 13/16 Janzen, Doug Direct Ownership Common Shares 15 - Acquisition under a prospectus 830,300 $0.300
AQSZF (MC $11 M) 2 Marketed Drugs + 3 Drugs nearing Approval
This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in early 2017 .Peak sales for these 4 drugs is between $40-45 Million according to Management which is HUGE for this microcap stock with a ridiculous market cap of $10 Million .Management alone holding over 16 Million shares Ceo just bought 840k shares at 0.30 a few days ago .GLTA
Aequus Pharma (AQS.V) (AQSZF)
Market-Cap: $11 M
Price: 0.22
Shares out: 54 Million
Presentation August 2016
http://www.aequuspharma.ca/Investors/Aequus%20Pharmaceuticals%20August%202016.pdf
Marketed Products :
Tacrolimus IR
Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)
Vistitan
•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.
Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017 <<< Licensed from Supernus Pharma (SUPN)
Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017 <<< Licensed from Supernus Pharma (SUPN)
NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)
AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.
Interview with Ceo Doug Janzen
http://business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canada
James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?
Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.
James West: Sure. Have you built a pharmaceutical company before, Doug?
Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.
AQSZF (MC $11 M) 2 Marketed Drugs + 3 Drugs nearing Approval
This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in early 2017 .Peak sales for these 4 drugs is between $40-45 Million according to Management which is HUGE for this microcap stock with a ridiculous market cap of $10 Million .Management alone holding over 16 Million shares Ceo just bought 840k shares at 0.30 a few days ago .GLTA
Aequus Pharma (AQS.V) (AQSZF)
Market-Cap: $11 M
Price: 0.22
Shares out: 54 Million
Presentation August 2016
http://www.aequuspharma.ca/Investors/Aequus%20Pharmaceuticals%20August%202016.pdf
Marketed Products :
Tacrolimus IR
Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)
Vistitan
•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.
Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017 <<< Licensed from Supernus Pharma (SUPN)
Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017 <<< Licensed from Supernus Pharma (SUPN)
NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)
AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.
Interview with Ceo Doug Janzen
http://business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canada
James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?
Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.
James West: Sure. Have you built a pharmaceutical company before, Doug?
Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.
AQSZF (MC $10 M) 2 Marketed Drugs + 3 close to Approval including a Potential Blockbuster = SUPER LIFETIME OPPORTUNITY !!!!
This undiscovered low float rocket is definitely the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Get some of this Goldmine before she gets discovered .Management alone holding over 16 Million shares Ceo bought 840k shares at 0.30 just a few days ago .GLTA
Aequus Pharma (AQS.V) (AQSZF)
Market-Cap: $10 M
Price: 0.21
Shares out: 54 Million
Presentation August 2016
http://www.aequuspharma.ca/Investors/Aequus%20Pharmaceuticals%20August%202016.pdf
Monster Pipeline
http://www.aequuspharma.ca/_images/content/Slide1.PNG?Action=thumbnail&algorithm=fill_proportional&width=750
Tacrolimus IR
Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)
Vistitan
•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.
Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017
Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017
NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)
AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.
Shorted this Junk again at $31 the stock is brutally overbought and i dont see any potential in their migraine drug which is still years away from the market IF ever . The Market is overflooded with very very cheap generic drugs for migraine so how they will make money ?
Without the almost zero interest and massive printing of worthless dollars by FED Mafia then such scams would not trade at these astronomical levels . The whole stock market is a mega bubble which is close to implode .
Shorted this junk at $32.20 yesterday now out at $30 it was a good deal for me
$1.5 BILLION SCAM / BURNING $60 M PER Q / RUNNING OUT OF CASH / NOTHING IN PIPELINE = EVEN IF THE DRUG IS APPROVED IT WILL NOT COVER THEIR HEAVY QUARTERLY LOSS . BIGGEST PONZI SCHEME BUBBLE HERE IN THE SECTOR = FAIR VALUE IS $8-10 AT BEST
IntelGenx Technologies Corp (OTCMKTS:IGXT) On The Verge Of A Breakout
http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-on-the-verge-of-a-breakout/116919/